641 reports of this reaction
3.2% of all TOBRAMYCIN SULFATE reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for TOBRAMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 641 FDA adverse event reports linking TOBRAMYCIN SULFATE to DYSPNOEA. This represents approximately 3.2% of all 20,334 adverse event reports for this drug.
Patients taking TOBRAMYCIN SULFATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among TOBRAMYCIN SULFATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for TOBRAMYCIN SULFATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 641 FDA reports for TOBRAMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.2% of all adverse event reports for TOBRAMYCIN SULFATE, making it a notable side effect.
If you experience dyspnoea while taking TOBRAMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.